May 28, 2026

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Conexiant

May 27, 2026

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

Conexiant

May 27, 2026

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Conexiant

May 27, 2026

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

Conexiant

May 27, 2026

Top 10 Evidence-Based Essentials in Family Medicine

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

Conexiant

May 27, 2026

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Conexiant

May 26, 2026

Birthweight, Childhood BMI: What Drives the Link?

Mendelian randomization analyses linked higher birthweight with greater mid-childhood height but the connection could reflect genetic factors related to skeletal growth.

Conexiant

May 26, 2026

Vitamin D May Reflect Myopia Risk

Narrative review linked lower vitamin D levels to greater myopia risk and higher omega-3 intake to lower risk, though outdoor exposure may explain the vitamin D association.

Conexiant

May 26, 2026

Semaglutide Reduced Nicotine Craving in Small Trial

Phase 2a trial found reduced nicotine craving and weight loss with semaglutide, but no significant between-group difference in cigarettes smoked per day.

Conexiant

May 21, 2026

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Conexiant